Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data

Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data PURPOSETo create an algorithm to identify incident epithelial ovarian cancer cases in claims-based data sets and evaluate performance of the algorithm using SEER-Medicare claims data.METHODSWe created a five-step algorithm on the basis of clinical expertise to identify incident epithelial ovarian cancer cases using claims data for (1) ovarian cancer diagnosis, (2) receipt of platinum-based chemotherapy, (3) no claim for platinum-based chemotherapy but claim for tumor debulking surgery, (4) removed cases with nonplatinum chemotherapy, and (5) removed patients with prior claims with personal history of ovarian cancer code to exclude prevalent cases. We evaluated algorithm performance using SEER-Medicare claims data by creating four cohorts: incident epithelial ovarian cancer, a 5% random sample of cancer-free Medicare beneficiaries, a 5% random sample of incident nonovarian cancer, and prevalent ovarian cancer cases.RESULTSUsing SEER tumor registry data as the gold standard, our algorithm correctly classified 89.9% of incident epithelial ovarian cancer cases (cohort n = 572) and almost 100% of cancer-free controls (n = 97,127), nonovarian cancer (n = 714), and prevalent ovarian cancer cases (n = 3,712). The overall algorithm sensitivity was 89.9%, the positive predictive value was 93.8%, and the specificity and negative predictive value were > 99.9%. Patients were more likely to be correctly classified as incident ovarian cancer if they had stage III or IV disease compared with early stage I or II disease (93.5% v 83.7%, P < .01), and grade 1-4 compared with unknown grade tumors (93.8% v 81.4%, P < .01).CONCLUSIONOur algorithm correctly identified most incident epithelial ovarian cancer cases, especially those with advanced disease. This algorithm will facilitate research in other claims-based data sets where cancer registry data are unavailable. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO: Clinical Cancer Informatics Wolters Kluwer Health

Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data

Download PDF
10 pages

Loading next page...
 
/lp/wolters-kluwer-health/algorithm-to-identify-incident-epithelial-ovarian-cancer-cases-using-tB5hj76piS
Publisher
Wolters Kluwer Health
Copyright
© 2022 by American Society of Clinical Oncology
eISSN
2473-4276
DOI
10.1200/cci.21.00187
Publisher site
See Article on Publisher Site

Abstract

PURPOSETo create an algorithm to identify incident epithelial ovarian cancer cases in claims-based data sets and evaluate performance of the algorithm using SEER-Medicare claims data.METHODSWe created a five-step algorithm on the basis of clinical expertise to identify incident epithelial ovarian cancer cases using claims data for (1) ovarian cancer diagnosis, (2) receipt of platinum-based chemotherapy, (3) no claim for platinum-based chemotherapy but claim for tumor debulking surgery, (4) removed cases with nonplatinum chemotherapy, and (5) removed patients with prior claims with personal history of ovarian cancer code to exclude prevalent cases. We evaluated algorithm performance using SEER-Medicare claims data by creating four cohorts: incident epithelial ovarian cancer, a 5% random sample of cancer-free Medicare beneficiaries, a 5% random sample of incident nonovarian cancer, and prevalent ovarian cancer cases.RESULTSUsing SEER tumor registry data as the gold standard, our algorithm correctly classified 89.9% of incident epithelial ovarian cancer cases (cohort n = 572) and almost 100% of cancer-free controls (n = 97,127), nonovarian cancer (n = 714), and prevalent ovarian cancer cases (n = 3,712). The overall algorithm sensitivity was 89.9%, the positive predictive value was 93.8%, and the specificity and negative predictive value were > 99.9%. Patients were more likely to be correctly classified as incident ovarian cancer if they had stage III or IV disease compared with early stage I or II disease (93.5% v 83.7%, P < .01), and grade 1-4 compared with unknown grade tumors (93.8% v 81.4%, P < .01).CONCLUSIONOur algorithm correctly identified most incident epithelial ovarian cancer cases, especially those with advanced disease. This algorithm will facilitate research in other claims-based data sets where cancer registry data are unavailable.

Journal

JCO: Clinical Cancer Informatics – Wolters Kluwer Health

Published: Mar 21, 2022

References

  • Cancer statistics, 2019
    Siegel, RL; Miller, KD; Jemal, A
  • Updates and new options in advanced epithelial ovarian cancer treatment
    Kurnit, KC; Fleming, GF; Lengyel, E
  • Practical guide to surgical data sets: Medicare claims data
    Ghaferi, AA; Dimick, JB
  • Identifying health outcomes in healthcare databases
    Lanes, S; Brown, JS; Haynes, K
  • Risk of cancer in infertile women: Analysis of US claims data
    Murugappan, G; Li, S; Lathi, RB
  • Antibiotic use and risk of gynecological cancer
    Tamim, HM; Musallam, KM; Al Kadri, HM
  • National trends in extended procedures for ovarian cancer debulking surgery
    Jones, NL; Chen, L; Chatterjee, S
  • Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes
    Matsuo, K; Chang, EJ; Matsuzaki, S
  • Care delivery patterns, processes, and outcomes for primary ovarian cancer surgery: A population-based review using a national administrative database
    Shakeel, S; Elit, L; Akhtar-Danesh, N
  • Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States
    Charo, LM; Jou, J; Binder, P
  • Cost of care for the initial management of ovarian cancer
    Bercow, AS; Chen, L; Chatterjee, S
  • Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer
    Harrison, RF; Fu, S; Sun, CC
  • Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population
    Warren, JL; Klabunde, CN; Schrag, D
  • Frequency and determinants of missing data in clinical and prognostic variables recently added to SEER
    Kim, HM; Goodman, M; Kim, BI
  • An algorithm for the use of Medicare claims data to identify women with incident breast cancer
    Nattinger, AB; Laud, PW; Bajorunaite, R
  • Evaluation of three algorithms to identify incident breast cancer in Medicare claims data
    Gold, HT; Do, HT
  • Development and validation of an algorithm to identify endometrial adenocarcinoma in US administrative claims data
    Esposito, DB; Banerjee, G; Yin, R
  • An approach to identifying incident breast cancer cases using Medicare claims data
    Freeman, JL; Zhang, D; Freeman, DH
  • Development and validation of coding algorithms to identify patients with incident lung cancer in United States healthcare claims data
    Beyrer, J; Nelson, DR; Sheffield, KM
  • A method to predict breast cancer stage using Medicare claims
    Smith, GL; Shih, YC; Giordano, SH
  • Validation of an algorithm for claims-based incidence of prostate cancer
    Parlett, LE; Beachler, DC; Lanes, S
  • Use of Medicare hospital and physician data to assess breast cancer incidence
    Warren, JL; Feuer, E; Potosky, AL
  • Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province: Using algorithms to determine breast and colorectal cancer recurrence
    Lambert, P; Pitz, M; Singh, H
  • Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology
    Armstrong, DK; Alvarez, RD; Bakkum-Gamez, JN
  • Treatment of epithelial ovarian cancer
    Kuroki, L; Guntupalli, SR
  • Practical guide to surgical data sets: Surveillance, Epidemiology, and End Results (SEER) database
    Doll, KM; Rademaker, A; Sosa, JA
  • Potential for cancer related health services research using a linked Medicare-tumor registry database
    Potosky, AL; Riley, GF; Lubitz, JD
  • A validation study of administrative claims data to measure ovarian cancer recurrence and secondary debulking surgery
    Livaudais-Toman, J; Egorova, N; Franco, R
  • SEER cancer stat facts: Ovarian cancer